Vittoria Biotherapeutics (Private Financing)
Funding Details
- Awarder
- Inbox
- Date Award
- November 12, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $25,000,000
Company Info
- Traction
- VIPER-101 clinical trial is actively recruiting patients.
- Organizations Involved
- University of Pennsylvania
- Company Description
- Vittoria Biotherapeutics, Inc. is a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases. The company’s proprietary Senza5 platform technology enhances T cell effector function through gene editing, with a focus on oncology and autoimmune diseases.
- Market
- Oncology
- Location
- Philadelphia, Pennsylvania, United States
- Coinvestors
- Valley Forge Investment Corporation, Global BioAccess Fund, Hatch Biofund, Agent Capital, Tellus BioVentures, NYBC Ventures, University of Pennsylvania